Search
Close this search box.

Category

Category

A universidade de inteligência artificial de Abu Dhabi cria departamentos dedicados à robótica e às ciências informáticas para responder à crescente procura mundial

ABU DHABI, Emirados Árabes Unidos, Aug. 04, 2023 (GLOBE NEWSWIRE) — A Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) estabeleceu dois novos departamentos e quatro programas de pós-graduação associados dedicados à robótica e à ciência da computação, satisfazendo a crescente procura global por estas disciplinas, sendo esperado que atinjam,

جامعة محمد بن زايد للذكاء الاصطناعي تطلق برامج في علم الروبوتات وعلوم الحاسوب

تلبية للطلب المتزايد على هذه التخصصات على مستوى العالم أبوظبي، الإمارات العربية المتحدة، 3 أغسطس 2023: أطلقت جامعة محمد بن زايد للذكاء الاصطناعي قسمين جديدين يشملان مجالي علم الروبوتات وعلوم الحاسوب، وذلك تلبية للطلب العالمي المتزايد على هذين التخصصين، إذ من المتوقع أن يصل الطلب إلى 225 مليار دولار[i] في

Zenas BioPharma annonce la publication d’une étude de phase 2 sur l’obéxélimab, un traitement expérimental pour la maladie liée aux IgG4 (ML-IgG4), dans The Lancet Rheumatology

L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez la plupart des patients atteints de ML-IgG4 active Les résultats soutiennent la poursuite du développement de l’obéxélimab pour le traitement de la ML-IgG4 et potentiellement d’autres maladies auto-immunes à médiation

Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology

Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes com IgG4-RD ativa Os resultados apoiam o desenvolvimento contínuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condições autoimunes mediadas por células B WALTHAM, Mass., Aug. 02, 2023

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a

Conagen and Sumitomo Chemical jointly develop a new era of renewable carbon materials

Bedford, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Conagen, the bioplatform innovator and biomanufacturer, and Sumitomo Chemical, Japan’s leading chemical company, have announced to jointly develop p-hydroxystyrene (HS) and its polymer, poly p-hydroxystyrene (PHS), using a combination of biosynthesis, chemosynthesis, and polymerization. The monomer and the polymer are 100% renewable

WATKINS WELLNESS EXPANDS INTO SAUNA CATEGORY THROUGH THE ACQUISITION OF SAUNA360

Vista, California, July 31, 2023 (GLOBE NEWSWIRE) — Watkins Wellness, a leader in hot tubs and aquatic fitness systems, today announced the expansion of its portfolio of personal well-being products and entry into the sauna category as a result of the pending acquisition of Sauna360 Group Oy (“Sauna360”) by Watkins